UK Life Sciences

Working with Industry - HCS as Catalysts of Technology Adoption

Dr Darren Clark, CEOMedilink East Midlands

UK Life Sciences

Reproduced from HM Government’s Strength & Opportunity Report 2011

Regional StrengthsMed Tech Companies

Reproduced from HM Government’s Strength & Opportunity Report 2011

40% of all companies

+ Largest Biotech Cluster in East of England

Common Goal

1st Challenge:New Product Development

Identify customer need Identify solution Translate into product

Market to customerEverybody’s Happy

Traditional Markets

NPDin Healthcare

Clinician

PatientCommissioner

Trust

But who is the

customer for health products?

2nd Challenge:Complex Innovation Landscape

National

NICE

NIC

Researchers

UniversitiesResearchCouncils

IMRCs /Catapults

Companies

Medilinks

TSB/BIS CCGs

HealthTechnologies KTN

EUCOMED ABHI / BIVDA

NHS Trusts/doctors etcCLAHRC /

BRUs/ AHSC / HTCs

EU Commission

DH / NHS

FCO

Companies

Professional Institutions

International Regional

NIHR

NTAC

Medilink UK

Medilink Model

• Sector Specific

• Industry association

• Membership based

• Not-for-profit

• Geographical focus

• Facilitate collaborations:

Medilink UK

BioBusiness NIMedilink East Midlands Medilink North West Medilink South WestMediWalesMedilink West MidlandsMedilink Yorkshire & HumberSEHTA

›1,000 members

Working Together

Wealth Health

Wealth Health

HCS

Contact for Further Information

Dr Darren ClarkChief Executive

Medilink East MidlandsBioCity NottinghamPennyfoot Street

NottinghamNG1 1GF

Tel: 0115 912 4330Fax: 0115 912 4331

e-mail: darren@medilinkem.comweb: www.medilinkem.com